/

Società

Ce

Non verificato

Cellares

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMercato del lavoroSalute

26 comunicati stampa

Guarda tutti i comunicati

10/06/2026

Cellares Joins New American Industrial Alliance, Advancing U.S. Biopharmaceutical Manufacturing Independence

Fonte

Emittente

1.00

0

09/06/2026

Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D

Fonte

Emittente

1.00

0

03/06/2026

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Fonte

Emittente

1.00

0

11/05/2026

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence

Fonte

Emittente

1.00

0

28/04/2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Fonte

Emittente

1.00

0

14/04/2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Fonte

Emittente

1.00

0

18/02/2026

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

Fonte

Emittente

1.00

0

03/02/2026

Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies

Fonte

Emittente

1.00

0

28/01/2026

Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

Fonte

Emittente

1.00

0

12/01/2026

Mercato del lavoro

Industria

Biotecnologia

Sanità

Salute

Farmaceutica

Scienza

Cellares amplia la rete globale di Smart Factory con una sede centrale europea nei Paesi Bassi

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0